Takeda's ORZEYFUL Wins FDA Approval As First Orexin Therapy For Narcolepsy Type 1; U.S. Launch Planned Following DEA Scheduling

Loading news article.

Takeda's ORZEYFUL Wins FDA Approval As First Orexin Therapy For Narcolepsy Type 1; U.S. Launch Planned Following DEA Scheduling | WAPE

Article summary